NCT02978482 2021-08-18A Phase 1/2 Study of Durvalumab(MEDI4736) and Tremelimumab in Chinese Patients With Advanced MalignanciesAstraZenecaPhase 1 Completed26 enrolled
NCT04216082 2020-01-02A Study of Anlotinib in Subjects With Advanced MalignancyChia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 2 Completed93 enrolled